{"url_path":"/sec/cpix/8-k/2026-07-01/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ****Financial Statements and Exhibits**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1087294/0001104659-26-079871-index.html","accession_number":"0001104659-26-079871","cik":"0001087294","ticker":"CPIX","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1087294/0001104659-26-079871-index.html","primary_entity_key":"0001087294","primary_entity_name":"CUMBERLAND PHARMACEUTICALS INC"},"word_count":297,"has_tables":true,"body_markdown":"**Item 9.01****Financial Statements and Exhibits**\n\n \n\n(b) Filed herewith as Exhibit 99.2 are the unaudited pro forma condensed\nbalance sheet as of March 31, 2026, and the unaudited pro forma condensed statements of operations for the years ended December 31, 2025\nand 2024, and the three months ended March 31, 2026.\n\n \n\n(d) Exhibits\n\n \n\n**Exhibit No.**\n \n**Description**\n\n \n \n \n\n[2.1*](https://www.sec.gov/Archives/edgar/data/1087294/000110465926047335/tm2611622d1_ex2-1.htm)\n \n[Asset Purchase Agreement, dated as of April 22, 2026, by and among Cumberland Pharmaceuticals Inc., Nuvo Pharmaceuticals (Ireland) DAC, and Apotex Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 23, 2026)](https://www.sec.gov/Archives/edgar/data/1087294/000110465926047335/tm2611622d1_ex2-1.htm)\n\n \n \n \n\n[2.2*](tm2619330d1_ex2-2.htm)\n \n[Amendment No. 1 to the Asset Purchase Agreement, dated as of July 1, 2026, by and between Cumberland Pharmaceuticals Inc. and Nuvo Pharmaceuticals (Ireland) DAC](tm2619330d1_ex2-2.htm)\n\n \n \n \n\n[99.1](tm2619330d1_ex99-1.htm)\n \n[Press Release, dated as of July 1, 2026, announcing the closing of the Transaction](tm2619330d1_ex99-1.htm)\n\n \n \n \n\n[99.2](tm2619330d1_ex99-2.htm)\n \n[Unaudited condensed pro forma financial statements of Cumberland Pharmaceuticals Inc., consisting of the unaudited pro forma condensed balance sheet as of March 31, 2026, and the unaudited pro forma condensed statements of operations for the years ended December 31, 2025 and 2024, and the three months ended March 31, 2026](tm2619330d1_ex99-2.htm)\n\n \n \n \n\n104\n \nCover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)\n\n \n\n*Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules or exhibits upon request by the U.S. Securities and Exchange Commission.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \nCumberland Pharmaceuticals Inc.\n\n \n \n\nDated: July 1,\n2026\nBy:\n*/s/ A. J. Kazimi*\n\n \n \nA. J. Kazimi\n\n \n \nChief Executive Officer"}